Veracyte, MaviDx Ink Agreement to Develop COVID-19 Assay

Jul 29, 2020

|

NEW YORK – South San Francisco-based Veracyte and MaviDx said on Wednesday they have signed an agreement for MaviDx to develop ultra-high throughput genomic testing for SARS-CoV-2 on Veracyte's nCounter diagnostic platform.

As part of the collaboration, Miami-based MaviDx will develop, validate, secure regulatory approvals for, and commercialize SARS-CoV-2 and other infectious disease tests, including for influenza, on the nCounter system.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Featured White Papers

Use of the LumiraDx SARS-CoV-2 Antigen Test in Pediatric Practice

Performance Evaluation of the LumiraDx SARS-CoV-2 Antigen Test to Aid Diagnosis of Acute COVID-19 at the Point of Care

An Evaluation of the Detection of SARS-CoV-2 Antigen in a Cohort of Symptomatic and Asymptomatic Patients: Report from the Evaluation of SKUP

Agena Bioscience’s SARS-CoV-2 Tests: Providing Resilience Against the Emergence of New Variants

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

17

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Mar

25

Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Menu

Veracyte, MaviDx Ink Agreement to Develop COVID-19 Assay

To read the full story....

Breaking News

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets

New Products Posted to GenomeWeb: Purigen Biosystems, Zymo Research, Qiagen, More

People in the News: New Appointments at Precipio, ERS Genomics, Omniome, PierianDx, More

In Brief This Week: Invenio Genetics, Swift Biosciences, Caris Life Sciences, and More

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

The Scan

Letter Urges New Inquiry

Great Apes Get Shots, Too

Woodcock on Vaccines, More

Science Paper Examines Molecular Contributors to Kidney Fibrosis

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

What's Popular?

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

At AGBT, Two Labs Share SARS-CoV-2 Genomic Surveillance Experience

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Fulgent Genetics Q4 Revenues Skyrocket

Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

Sponsorships